The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome

Bećarevic, Mirjana; Stojanović, Ljiljana; Ignjatović, Svetlana; Dopsaj, Violeta

doi:10.1007/s10067-016-3230-0

Cited by 12 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bećarević et al. have reported that history of RM was associated with positivity for aAnxA5 IgM and lupus anticoagulant 22 . Many studies have shown that aAnxA5 is associated with RM patients 16,23–25 .…”

Section: Introductionmentioning

confidence: 99%

“…21 Bećarević et al have reported that history of RM was associated with positivity for aAnxA5 IgM and lupus anticoagulant. 22 Many studies have shown that aAnxA5 is associated with RM patients. 16,[23][24][25] However, it is not yet clear whether aAnxA5 was the cause or consequence of miscarriage, as these studies were performed during pregnancy or after miscarriage.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preconception anti‐annexin A5 antibodies are associated with subsequent live birth in women with recurrent miscarriage: A retrospective study from China

Mu,

Wang,

Liu

et al. 2024

American J Rep Immunol

View full text Add to dashboard Cite

ProblemTo evaluate the correlation between the antiannexin A5 antibodies (aAnxA5) multiples of median (MOM) and subsequent pregnancy outcomes in women with recurrent miscarriage (RM).MethodsTotally, 310 RM women were included in this study and grouped into tertiles according to their MOM of preconception aAnxA5 circulating levels determined by ELISA. The effect of aAnxA5 on the pregnancy outcomes was performed using multiple logistic regression. The outcomes included early miscarriage (before 10 weeks of gestation), late miscarriage (between 10 and 24 weeks), ongoing pregnancy (beyond 10 weeks), and live birth (after 24 weeks) characterized by pregnancy with fetal heartbeat.ResultsFor each unit increase in aAnxA5 MOM, the odds of live birth after 24 weeks and ongoing pregnancy were reduced by 40.2% (OR = .598; 95%CI 0.406–0.882, P = .010) and 38.1% (OR = .619; 95%CI 0.424–0.904, P = .013), respectively, after adjusting for demographic and clinical characteristics. The rise in aAnxA5 MOM was associated with an increased risk of early miscarriage (OR = 1.616; 95%CI 1.106–2.361, P = .013) and miscarriage (early + late miscarriage) (OR = 1.671; 95%CI 1.134–2.464, P = .010). Further subgroup analyses showed a decreased risk of live birth rates after 24 weeks of gestation in the two subgroups: maternal age ≥35 years (OR = .131; 95%CI 0.026–0.652), and previous pregnancy loss ≥ 3 (OR = .381; 95%CI 0.173–0.837).ConclusionsHigher preconception aAnxA5 MOM levels in women with RM may be linked with a decreased risk of live birth after 24 weeks and an increased risk of early miscarriage, especially in individuals aged ≥35 years or with previous pregnancy losses ≥3.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Preconception anti‐annexin A5 antibodies are associated with subsequent live birth in women with recurrent miscarriage: A retrospective study from China

Mu,

Wang,

Liu

et al. 2024

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome

Bećarevic

2016

Rheumatol Int

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is characterized by thromboses and/or pregnancy losses. Laboratory criterion for the diagnosis of APS is the presence of antiphospholipid antibodies (anticardiolipin, anti-beta2-glycoprotein I (aβ2gpI) and lupus anticoagulant). On the one hand, the latest classification criteria for the diagnosis of APS emphasized that thrombotic manifestations of the syndrome should be without any signs of an inflammatory process, while on the other hand, some recent reports have suggested that APS is a "pro-inflammatory state." This article is focused on the importance of TNF-alpha and annexin A2 (anxA2) for patients with vascular (thrombotic) manifestations of the primary APS. The classic antithrombotic and antiplatelet therapy does not protect APS patients from the development of recurrent thrombosis. Therefore, an urgent need for the introduction of new therapeutic approaches in the treatment of APS patients is obvious. This review provides a rationale for the necessity for the use of immunomodulatory medications that could interfere with β2gpI binding to its receptor(s), such as anxA2, and/or inhibit TNF-alpha activity.

show abstract

Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients

et al. 2016

View full text Add to dashboard Cite

The aim of this study was to evaluate oxidative stress markers and it relations to endothelial damage as risk factor for thrombosis in patients with primary (PAPS) and secondary (SAPS) antiphospholipid syndrome (APS) in correlation to traditional risk factors. Flow-mediated (FMD) and nitroglycerine (NMD)-induced dilation of the brachial artery were studied in 140 APS patients (90 PAPS, 50 SAPS) and 40 controls matched by age, sex, and conventional risk factors for atherosclerosis. Markers of oxidative stress, lipid hydroperoxydes (LOOH), advanced oxidation protein products (AOPP), total sulfhydryl groups (tSHG), and paraoxonase 1 activity (PON1) were determined by spectrophotometric method. Oxidative stress dominates in APS patients. LOOH and AOPP correlate to lipid fractions (p < 0.05), unlike PON1, tSHG that correlated to antiphospholipid antibody positivity (p < 0.05). FMD was lower in APS patients comparing to controls (p < 0.001). Cholesterol is independent variable for FMD impairment in control group (p = 0.011); LOOH in PAPS (p = 0.004); LOOH, aCL, and triglycerides in SAPS patients (p = 0.009, p = 0.049, and p = 0.012, respectively). Combined predictive of aCL and LOOH is better for FMD impairment than LOOH alone in both PAPS and SAPS patients (AUC 0.727, p = 0.001, 95 % CI 0.616-0.837 and AUC 0.824, p˂0.001, 95 % CI 0.690-0.957, respectively). Lipid peroxidation is independent predictor for endothelial dysfunction in APS patients. We demonstrated synergistic effect of aCL and LOOH as risk for endothelial impairment in both PAPS and SAPS patients.

show abstract

The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome

Cited by 12 publications

References 19 publications

Preconception anti‐annexin A5 antibodies are associated with subsequent live birth in women with recurrent miscarriage: A retrospective study from China

Preconception anti‐annexin A5 antibodies are associated with subsequent live birth in women with recurrent miscarriage: A retrospective study from China

TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome

Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients

Contact Info

Product

Resources

About